Vaccines and Infectious Diseases (vaccine research, development and clinical studies)
| Title | Εμβόλια και Λοιμώδη Νοσήματα (Έρευνα, ανάπτυξη και κλινικές μελέτες εμβολίων) / Vaccines and Infectious Diseases (vaccine research, development and clinical studies) |
| Code | ΤΙΜΕΛΝΑ1 |
| Faculty | Health Sciences |
| School | Medicine |
| Cycle / Level | 2nd / Postgraduate |
| Teaching Period | Winter/Spring |
| Coordinator | Georgios Papazisis |
| Common | No |
| Status | Active |
| Course ID | 600022188 |
Programme of Study: DPMS "EMVOLIA KAI LOIMŌDĪ NOSĪMATA" (2022-sīmera)
Registered students: 20
| Orientation | Attendance Type | Semester | Year | ECTS |
|---|---|---|---|---|
| KORMOS | Compulsory Course | 1 | 1 | 6 |
| Academic Year | 2025 – 2026 |
| Class Period | Winter |
| Faculty Instructors | |
| Instructors from Other Categories |
|
| Weekly Hours | 3 |
| Total Hours | 39 |
| Class ID | 600290156
|
Course Type 2021
General Foundation
Mode of Delivery
- Face to face
- Distance learning
Digital Course Content
- e-Study Guide https://qa.auth.gr/en/class/1/600290156
- At the Website of the School:
- eLearning:
Language of Instruction
- Greek (Instruction, Examination)
Learning Outcomes
1. Understand the principles governing preclinical research and development studies of new drugs and vaccines.
2. Understand the principles governing Phase I, II, and III clinical trials of research and development of new drugs and vaccines.
3. Understand the principles governing comparative clinical trials.
4. Understand the regulatory framework for the evaluation of drugs and vaccines.
5. Understand the basic principles of Observational and Intervention studies.
6. Gain deeper understanding of vaccine development studies against SARS-CoV-2.
General Competences
- Retrieve, analyse and synthesise data and information, with the use of necessary technologies
- Work in an interdisciplinary team
- Generate new research ideas
Course Content (Syllabus)
- Drug Research and Development - Preclinical Studies
- Drug Research and Development - Clinical Phase
- Observational and Interventional Studies, Phase I Studies
- Phase II, III, IV Studies - post-marketing Studies
- Regulatory Framework for Drug and Vaccine Evaluation
- Clinical Trials of Vaccines against SARS-CoV-2
Educational Material Types
- Notes
- Slide presentations
- Video lectures
Use of Information and Communication Technologies
Use of ICT
- Use of ICT in Course Teaching
- Use of ICT in Communication with Students
- Use of ICT in Student Assessment
Course Organization
| Activities | Workload | ECTS | Individual | Teamwork | Erasmus |
|---|---|---|---|---|---|
| Lectures | 55 | ||||
| Reading Assigment | 30 | ||||
| Field trips and participation in conferences / seminars / activities | 25 | ||||
| Written assigments | 20 | ||||
| Exams | 20 | ||||
| Total | 150 |
Student Assessment
Student Assessment methods
- Written Exam with Multiple Choice Questions (Formative, Summative)
- Oral Exams (Formative, Summative)
Bibliography
Course Bibliography (Eudoxus)
• COVID-19 vaccines adverse events: potential molecular mechanisms.Lamprinou M, …Papazisis G. Immunol Res. 2023
• Predicting the next pandemic: VACCELERATE ranking of the WorldHealth Organization's Blueprint forAction toPreventEpidemics.Salmanton-García J, et al. VACCELERATE Consortium. Travel Med Infect Dis. 2023 Dec 6;57:102676.
• Serum Proteome Signatures of Anti-SARS-CoV-2 Vaccinated Healthcare Workers in Greece Associated with Their Prior Infection Status.Stamoula E, Sarantidi E, Dimakopoulos V, Ainatzoglou A, Dardalas I, Papazisis G, Kontopoulou K, Anagnostopoulos AK. Int J Mol Sci. 2022 Sep 5;23(17):10153. doi:
• Antibody titers after a third dose of the SARS-CoV-2 BNT162b2 vaccine in immunocompromised adults in Greece: Is a fourth dose necessary? Kontopoulou K, Nakas CT, Belai C, Papazisis G. J Med Virol. 2022
• Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive. Kontopoulou K,…Papazisis G. Vaccine. 2021 Aug 23;39(36):5078-5081.
• Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers.Kontopoulou K,…Papazisis G. J Med Microbiol. 2021 Aug;70(8):001387. doi:
• Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study.Kontopoulou K, …Papazisis G. Aging Clin Exp Res. 2021 Dec;33(12):3385-3389.
Additional bibliography for study
Σημειώσεις και ppt μεσω elearning
Last Update
26-02-2024
